Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Jun 2008

Le Tourneau Christophe, Vidal Laura, Siu Lillian L

Abstract excerpt

Molecularly targeted therapies aim to interfere with molecular mechanisms, selectively involved in carcinogenesis and tumor growth in order to optimize the efficacy and minimize the side effects of anticancer treatment. In the last decade, several receptor tyrosine kinase inhibitors (TKIs) have become approved for therapeutic use in hematological malignancies as well as solid tumors. However, a major challenge...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endothelial Cells

Share to ErbB Receptors

Share to Gene Dosage

Share to Magnetic Resonance Imaging

Share to Neovascularization, Pathologic

Share to Receptors, Vascular Endothelial Growth Factor

Source

Identifiers

PMID: 18515176
DOI: 10.1016/j.drup.2008.04.001

Genes

EGFR
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.PMID 18515176Read ↗

Use of molecular markers for predicting therapy response in cancer patients.Semantic proximity Read ↗

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Semantic proximity Read ↗

Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.Semantic proximity Read ↗

Companion biomarkers: paving the pathway to personalized treatment for cancer.Semantic proximity Read ↗

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized MedicineSemantic proximity Read ↗

Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.Semantic proximity Read ↗

[Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].Semantic proximity Read ↗

Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.Semantic proximity Read ↗

Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.Semantic proximity Read ↗

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationSemantic proximity Read ↗

Companion diagnostic testing for targeted cancer therapies: an overview.Semantic proximity Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.